Skip to main content
Erschienen in: Rheumatology International 3/2012

01.03.2012 | Case Report

Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy

verfasst von: Wan-Hee Yoo

Erschienen in: Rheumatology International | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

A case of multiple organ tuberculosis (TBc) involving lung, pleura, and peritoneum in a 39-year-old man with long-standing ankylosing spondylitis (AS) treated with adalimumab was presented. The relationship between antitumor necrosis factor-α (anti-TNF-α) therapy and TBc was also reviewed. This case illustrates that TBc can develop in multiple organs during adalimumab therapy, and thus, the awareness of serious complications of multiple organs and atypical extrapulmonary pattern of TBc during anti-TNF-α therapy needs to be increased.
Literatur
1.
Zurück zum Zitat van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr, ATLAS Study Group (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146PubMedCrossRef van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr, ATLAS Study Group (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146PubMedCrossRef
2.
Zurück zum Zitat Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J (2006) ‘ASsessment in AS’ international working group; European League Against Rheumatism (ASAS/EULAR) recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65(4):442–452PubMedCrossRef Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J (2006) ‘ASsessment in AS’ international working group; European League Against Rheumatism (ASAS/EULAR) recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65(4):442–452PubMedCrossRef
3.
Zurück zum Zitat Toussirot E, Streit G, Wendling D (2007) Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review. Recent Pat Inflamm Allergy Drug Discov 1(1):39–47PubMedCrossRef Toussirot E, Streit G, Wendling D (2007) Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review. Recent Pat Inflamm Allergy Drug Discov 1(1):39–47PubMedCrossRef
4.
Zurück zum Zitat Strangfeld A, Listing J (2006) Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 20(6):1181–1195PubMedCrossRef Strangfeld A, Listing J (2006) Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 20(6):1181–1195PubMedCrossRef
5.
Zurück zum Zitat Azevedo VF, Parchen C, Coelho SA, Lacerda DC, Hirth CG (2009) Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab. Rheumatol Int 29(11):1381–1384PubMedCrossRef Azevedo VF, Parchen C, Coelho SA, Lacerda DC, Hirth CG (2009) Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab. Rheumatol Int 29(11):1381–1384PubMedCrossRef
6.
Zurück zum Zitat Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104PubMedCrossRef Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104PubMedCrossRef
7.
Zurück zum Zitat Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505PubMedCrossRef Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505PubMedCrossRef
8.
Zurück zum Zitat Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J (2006) Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54(2):678–681PubMedCrossRef Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J (2006) Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54(2):678–681PubMedCrossRef
9.
Zurück zum Zitat Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30(12):2563–2571PubMed Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30(12):2563–2571PubMed
10.
Zurück zum Zitat Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45PubMedCrossRef Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45PubMedCrossRef
11.
Zurück zum Zitat Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350(21):2167–2179PubMedCrossRef Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350(21):2167–2179PubMedCrossRef
12.
Zurück zum Zitat Rychly DJ, Dipiro JT (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25(9):1181–1192PubMedCrossRef Rychly DJ, Dipiro JT (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25(9):1181–1192PubMedCrossRef
13.
Zurück zum Zitat Scheinfeld N (2005) Adalimumab: a review of side effects. Expert Opin Drug Saf 4(4):637–641PubMedCrossRef Scheinfeld N (2005) Adalimumab: a review of side effects. Expert Opin Drug Saf 4(4):637–641PubMedCrossRef
14.
Zurück zum Zitat Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM (2004) Tuberculosis following the use of etarnecept, a tumor necrosis factor inhibitor. Clin Infect Dis 39(3):295–299PubMedCrossRef Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM (2004) Tuberculosis following the use of etarnecept, a tumor necrosis factor inhibitor. Clin Infect Dis 39(3):295–299PubMedCrossRef
15.
Zurück zum Zitat Bieber J, Kavanaugh A (2004) Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biological treatments. Rheum Dis Clin North Am 30(2):257–270PubMedCrossRef Bieber J, Kavanaugh A (2004) Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biological treatments. Rheum Dis Clin North Am 30(2):257–270PubMedCrossRef
16.
Zurück zum Zitat Antolín J, Azahara M, Hernández C, Blanco M, Mao L, Cigüenza R (2008) Tuberculous peritonitis after treatment with adalimumab. Scand J Infect Dis 40(8):677–678PubMedCrossRef Antolín J, Azahara M, Hernández C, Blanco M, Mao L, Cigüenza R (2008) Tuberculous peritonitis after treatment with adalimumab. Scand J Infect Dis 40(8):677–678PubMedCrossRef
17.
Zurück zum Zitat Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P, Miguel-de la Villa F (2007) Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol 26(3):452–453PubMedCrossRef Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P, Miguel-de la Villa F (2007) Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol 26(3):452–453PubMedCrossRef
18.
Zurück zum Zitat Endean AL, Barry SM, Young-Min SA (2009) Possible miliary tuberculosis during adalimumab therapy with negative gamma-IFN release assays. Rheumatology (Oxford) 48(3):319–320CrossRef Endean AL, Barry SM, Young-Min SA (2009) Possible miliary tuberculosis during adalimumab therapy with negative gamma-IFN release assays. Rheumatology (Oxford) 48(3):319–320CrossRef
19.
Zurück zum Zitat Carmona L, Hernández-García C, Vadillo C, Pato E, Balsa A, González-Alvaro I, Study Group EMECAR (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30(7):1436–1439PubMed Carmona L, Hernández-García C, Vadillo C, Pato E, Balsa A, González-Alvaro I, Study Group EMECAR (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30(7):1436–1439PubMed
20.
Zurück zum Zitat Stas P, D’Hoore A, Van Assche G, Geboes K, Steenkiste E, Penninckx F, Rutgeerts P, Vermeire S (2006) Miliary tuberculosis following infliximab therapy for Crohn disease: a case report and review of the literature. Acta Gastroenterol Belg 69(2):217–220PubMed Stas P, D’Hoore A, Van Assche G, Geboes K, Steenkiste E, Penninckx F, Rutgeerts P, Vermeire S (2006) Miliary tuberculosis following infliximab therapy for Crohn disease: a case report and review of the literature. Acta Gastroenterol Belg 69(2):217–220PubMed
21.
Zurück zum Zitat Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149(3):177–184PubMed Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149(3):177–184PubMed
22.
Zurück zum Zitat Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, Richeldi L (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367(9519):1328–1334PubMedCrossRef Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, Richeldi L (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367(9519):1328–1334PubMedCrossRef
Metadaten
Titel
Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy
verfasst von
Wan-Hee Yoo
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 3/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1357-x

Weitere Artikel der Ausgabe 3/2012

Rheumatology International 3/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.